Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM Plus Chemotherapy Maintenance in Advanced NSCLC
NCT02900742Phase 3Completed
- Sponsor
- Shanghai University of Traditional Chinese Medicine
- Start
- Mar 2013
- Primary completion
- Dec 2016
- Modality
- Traditional Chinese Medicine Formula
01
Overview
Phase 3, randomised, double-blind trial of YiQiYangYinFang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai University of Traditional Chinese Medicine. Primary endpoint: Overall Survival at 2 months. Started Mar 2013; status: completed.
02
Drugs
YiQiYangYinFang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02900742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900742.